Antibody Screening Using Syngeneic Mouse Tumor Models
Many antibodies that target human immune checkpoints do not cross-react well to murine counterparts, making it difficult to test antibody efficacy in vivo. Biocytogen’s humanized models provide an excellent solution where the human extracellular domain replaces the mouse counterpart, thus allowing direct testing of anti-human antibodies in mice for in vivo efficacy assessments. At Biocytogen, many of our humanized mice are assessed for the following features, allowing for pre-clinical validation of novel antibodies:
- Expression of the humanized portion of the gene by RT-PCR & FACS whenever possible
- Lymphocyte development & cell subtypes in the spleen, thymus, lymph nodes at frequencies comparable to those observed in wildtype C57BL/6 mice
Similarly, Biocytogen has engineered several syngeneic models carrying humanized immune checkpoint genes or other tumor-associated antigens. These syngeneic models can be engrafted into our humanized immune checkpoint mice for robust anti-tumor efficacy studies. Many of our mouse models also carry multiple humanized genes, allowing for the evaluation of novel combination therapies for anti-tumor efficacy studies. View specific case studies in humanized CD3E mice below.
